

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Uncoupled human flavin-containing monooxygenase 3 releases superoxide radical in addition to hydrogen peroxide**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1727743> since 2020-02-17T16:37:03Z

*Published version:*

DOI:10.1016/j.freeradbiomed.2019.09.038

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

5  
6  
7  
8  
9  
10  
11  
12

This is the author's final version of the contribution published as:

[Gianluca Catucci, Chongliang Gao, Giulia Rampolla, Gianfranco Gilardi and  
Sheila J. Sadeghi\*, Uncoupled human flavin-containing monooxygenase 3  
releases superoxide radical in addition to hydrogen peroxide , Free Radical Biology  
and Medicine, 145, 2019, pagg. 250-255,  
<https://doi.org/10.1016/j.freeradbiomed.2019.09.038>]

The publisher's version is available at:

[<https://www.sciencedirect.com/science/article/pii/S0891584919308949?via%3Dihub>]

When citing, please refer to the published version.

Link to this full text:

[inserire l'handle completa, preceduta da <http://hdl.handle.net/>]

**Uncoupled human flavin-containing monooxygenase 3  
can release superoxide radical in addition to hydrogen peroxide**

Gianluca Catucci, Chongliang Gao, Giulia Rampolla, Gianfranco Gilardi and  
Sheila J. Sadeghi\*

*Department of Life Sciences and Systems Biology, University of Torino, Italy*

\* Corresponding author: Department of Life Sciences and Systems Biology, Via  
Accademia Albertina 13, 10123 Torino, Italy.  
Tel.: +39 011 6704528  
Fax: +39 011 6704643  
E-mail address: [sheila.sadeghi@unito.it](mailto:sheila.sadeghi@unito.it)

34 **Abstract**

35 Human flavin-containing monooxygenase 3 (hFMO3) is a drug-metabolizing enzyme capable  
36 of performing N- or S-oxidation using the C4a-hydroperoxy intermediate. In this work, we  
37 employ both wild type hFMO3 as well as an active site polymorphic variant (N61S) to unravel  
38 the uncoupling reactions in the catalytic cycle of this enzyme. We demonstrate that in addition  
39 to H<sub>2</sub>O<sub>2</sub> this enzyme also produces superoxide anion radicals as its uncoupling products. The  
40 level of uncoupling was found to vary between 50 and 70% (WT) and 90 to 98% (N61S) for  
41 incubations with NADPH and benzydamine over a period of 5 or 20 minutes, respectively. For  
42 the first time, we were able to follow the production of the superoxide radical in hFMO3, which  
43 was found to account for 13-18% of the total uncoupling of this human enzyme. Moreover,  
44 measurements in the presence or absence of the substrate show that the substrate lowers the  
45 level of uncoupling only related to the H<sub>2</sub>O<sub>2</sub> and not the superoxide radical. This is consistent  
46 with the entry point of the substrate in this enzyme's catalytic cycle.  
47 These findings highlight the importance of the involvement of hFMO3 in the production of  
48 radicals in the endoplasmic reticulum, as well as the relevance of single-nucleotide  
49 polymorphism leading to deleterious effects of oxidative stress.

50

51

52 Keywords: flavin-containing monooxygenase, hydrogen peroxide, superoxide radical,  
53 polymorphic variant, N61S, uncoupling.

54

## 55    **1. Introduction**

56    Human flavin-containing monooxygenase 3 (hFMO3) is a drug metabolizing enzyme expressed  
57    at high levels in the human liver [1-3]. Human FMO3 is the major human enzyme able to perform  
58    the monooxygenation of trimethylamine (TMA) yielding trimethylamine N-oxide (TMAO) [4].  
59    Impaired metabolism of its main substrate TMA is known to cause trimethylaminuria, a genetic  
60    disease in which affected individuals present high levels of TMA in both sweat and urine leading  
61    to a displeasing body odor [5,6]. The disease is caused by mutations of the hFMO3 gene that  
62    cause an altered activity of the enzyme and have direct consequences on the oxidation of TMA.  
63    One such mutation, N61S, leads to a polymorphic variant known to cause trimethylaminuria [7].  
64    On the other hand, the product of the reaction, TMAO, was recently found to be a risk factor for  
65    cardiovascular disease [8-10].

66    Previous characterization of pig liver FMO has shown how FMO is reduced by NADPH and  
67    upon binding of O<sub>2</sub> it can form a stable long-lived C4a-hydroperoxyflavin intermediate [11,12].  
68    This species reacts very well with soft nucleophiles performing a monooxygenase reaction,  
69    followed by the formation of water and the release of the oxidized NADP<sup>+</sup> cofactor [11,12].  
70    Nevertheless, recent work carried out with purified human FMO1, FMO2, FMO3 and FMO5  
71    have demonstrated how the human enzyme does not seem to form a long-lived intermediate  
72    and that the detachment of oxygen species from peroxyflavin might lead to uncoupling [13- 16].  
73    The uncoupling reaction, which is defined as the wastage of electrons and oxygen without  
74    oxidation of the substrate, can lead to the formation of reactive oxygen species (ROS) such as  
75    the superoxide radical and/or hydrogen peroxide. Earlier studies performed with pig FMO have  
76    highlighted the formation of superoxide anion radical at the rate of about 4% the total NADPH  
77    oxidized [17]. Formation of hydrogen peroxide, up to 41% of the total NADPH oxidized, has  
78    also been demonstrated in earlier work with purified rabbit lung FMO [18]. However, more

79 recently the human FMOs 1, 2 and 3 were found to release only H<sub>2</sub>O<sub>2</sub> after reduction by NADPH  
80 with no superoxide radical being observed [16].

81 In this work, since we had previously purified hFMO3 [19] and its polymorphic N61S variant  
82 [13], we set out to measure the uncoupling products of these enzymes in order to clarify whether  
83 the human enzyme also produces the superoxide radical or only hydrogen peroxide. To do so,  
84 we tested the ability of the enzyme to use the electrons provided by NADPH to perform the  
85 monooxygenation reaction, by quantifying both the amount of ROS (hydrogen peroxide and  
86 superoxide radical) and product formed. The N61S polymorphic variant was selected due to its  
87 poor binding affinity for NADP<sup>+</sup> leading to an acceleration of the C4a-hydroperoxyFAD  
88 intermediate decay [13], resulting in higher uncoupling.

89

## 90 **2. Material and Methods**

### 91 2.1 Cloning, expression and purification

92 The pJL2-hFMO3 plasmid constructed previously [19, 20] was used with QuikChange® site-  
93 directed mutagenesis kit (Stratagene) to produce N61S hFMO3 [13]. Human FMO3 gene  
94 containing a C-terminal poly-histidine tag was heterologously expressed in *E. coli* cells and  
95 purified as described previously [21]. The protein was stored at -80 °C in 50 mM KPi pH 7.4,  
96 20% glycerol with 1 mM EDTA. Protein purity and concentration was determined  
97 spectroscopically as described previously [13, 22].

### 98 2.2 NADPH oxidation, hydrogen peroxide and superoxide detection

99 All the reactions were carried out in the dark, in triplicates, in 96-well plates using a plate reader  
100 equipped with a uv-vis absorbance detector using 1.6 μM hFMO3, 160 μM NADPH and 0 or  
101 300 μM benzydamine in 50 mM KPi pH 7.4. The optical pathlength was 0.45 cm. The plate  
102 reader automatically takes into account the optical pathlength on the basis of the volume used

103 in the 96-well plates. For NADPH consumption reactions, mixtures were incubated at 37 °C.  
104 NADPH signal at 340 nm was monitored in time using  $6220 \text{ M}^{-1} \text{ cm}^{-1}$  as extinction coefficient.  
105 Preliminary controls were performed to establish reaction conditions that do not lead to  
106 undesired production of hydrogen peroxide by NADPH autoxidation. The controls are shown in  
107 Figure S1 where incubations of AMPLEX RED kit are reported with or without NADPH. Results  
108 indicate that under our experimental conditions there is no detectable contribution to hydrogen  
109 peroxide formation by NADPH. Basal NADPH consumption in the absence of the substrate was  
110 also tested (Figure S2).

111 Potential interference of benzydamine with the Amplex Red assay was evaluated by comparing  
112 identical assay conditions in the presence or absence of benzydamine. Figure S3 shows that  
113 there is no interference with the assay.

114 For every assay aimed at the quantification of hydrogen peroxide the amount of hydrogen  
115 peroxide in the unknown sample was determined using a calibration curve prepared with fresh  
116 hydrogen peroxide and run in parallel with the unknown samples.

117 For  $\text{H}_2\text{O}_2$  detection 50  $\mu\text{L}$  of reaction mixture was withdrawn from a well at each time point and  
118 mixed in an eppendorf containing 50  $\mu\text{L}$  of cold acetonitrile to terminate the reaction, centrifuged  
119 at 14000 rpm for 5 minutes and subjected to HPLC separation. The remaining 50  $\mu\text{L}$  of reaction  
120 mixtures were incubated with AMPLEX RED [16, 23, 24] and  $\text{H}_2\text{O}_2$  formation was quantified at  
121 571 nm by recording the spectrum of resorufin after 1 minute of incubation for each time point.  
122 In the absence of benzydamine all the steps were identical, but the reactions were not subjected  
123 to HPLC. In order to assess if benzydamine can be oxidized non-enzymatically by  $\text{H}_2\text{O}_2$  a  
124 reaction control was performed by incubating 20  $\mu\text{M}$  of with benzydamine at 37°C for 1 hour.  
125 The concentration of was chosen to reproduce the highest amount of present in the reaction  
126 mixture produced by the enzyme.

127 For superoxide radical detection, in order to exclude that the signal of cytochrome c reduction  
128 is not due to superoxide, 2 control reactions were performed. In the first control, the cytochrome  
129 c reduction experiment was performed in the presence of SOD using 10  $\mu$ M of cytochrome c.  
130 Figure S4, clearly shows that at this cytochrome c concentration there is no direct cytochrome  
131 c reduction by the enzyme. In the second control, cytochrome c reduction was performed in the  
132 absence/presence of SOD using 50  $\mu$ M of cytochrome c. The data presented in Figure S5,  
133 demonstrate that at this higher cytochrome c concentration there is a contribution of hFMO3 to  
134 direct cytochrome c reduction. Therefore, only the SOD inhibited part of the signal can be used  
135 to measure superoxide. The amount of superoxide matches what was previously found using  
136 10  $\mu$ M cytochrome c that is the optimal concentration to test cytochrome c reduction without  
137 the interference of direct reduction from hFMO3 by cytochrome c.

138 To calculate the amount of superoxide produced by hFMO3 an extinction coefficient of  $2.1 \times 10^4$   
139  $\text{M}^{-1}\text{cm}^{-1}$  was used which is the difference in the extinction coefficients between the reduced and  
140 oxidized forms and it was used because it takes into account only the amount of superoxide  
141 that is actually formed during the reaction. All analyses were carried out using 10  $\mu$ M horse  
142 heart cytochrome c (Sigma).

143

### 144 2.3 HPLC analysis

145 N-oxygenation of benzydamine by the wild type and N61S variant of hFMO3 were carried out  
146 as previously described [24, 25] and the amount of product determined by HPLC (Agilent-1200,  
147 Agilent Technologies, U.S.A.). Each sample was analyzed by HPLC equipped with  $4.6 \times 150$   
148 mm 5  $\mu$ m Eclipse XDB-C18 column at room temperature with the UV-visible detector set at  
149 308 nm for benzydamine N-oxide as described previously [25].

150



## 151 2.4 Calculation of the percentage of uncoupling

152

153 Uncoupling percentages were calculated by dividing the absolute rates of the rates of  
154 benzydamine oxidation by the NADPH consumption which yields the coupled reaction. The  
155 uncoupled reaction is given by the subtraction of the coupled reaction from the total reaction  
156 (including both coupled and uncoupled reactions).

157

## 158 2.5 Differential scanning calorimetry

159 In order to provide direct effects of hydrogen peroxide exposure differential scanning  
160 calorimetry experiments were carried out for hFMO3 following incubation of the enzyme with  
161 hydrogen peroxide. Differential scanning calorimetry was carried out as previously illustrated  
162 [13]

163

## 164 2.6 Statistical analyses


165 Statistical analyses were performed using Sigmaplot 11.0 software. Data calculations were  
166 carried out by repeated-measures of two-way ANOVA followed by Student-Newman-Keuls post  
167 hoc test. All experiments were executed in triplicates. Data are shown as mean  $\pm$  standard  
168 deviation. Differences among data points were considered significant when  $p < 0.05$ .

169

## 170 3. Results


171 In order to measure the uncoupling reactions of hFMO3, the NADPH oxidation activity of the  
172 purified WT enzyme was investigated by monitoring the kinetics of the decrease in absorbance  
173 of the reduced cofactor at 340 nm in time. NADPH by itself shows minimal oxidation in the  
174 absence of the enzyme, so the reaction can actually start only when both NADPH and hFMO3

are present (data not shown). The amount of H<sub>2</sub>O<sub>2</sub> produced was measured by mixing aliquots of each reaction, at different times after the start, with the AMPLEX red kit components [23]. We compared the H<sub>2</sub>O<sub>2</sub> produced by WT hFMO3 and its polymorphic variant, N61S. The latter, an active site mutant associated with trimethylaminuria is known to have impaired NADP<sup>+</sup> binding and lower activity [13]. The data obtained demonstrate how in the absence of the substrate benzydamine (BZD), N61S produces higher amounts of H<sub>2</sub>O<sub>2</sub> compared to WT (Fig 1). Interestingly WT showed steadily increased leakage while N61S had high leakage at the beginning of the incubation that decreased slowly after the first 15 minutes.




**Fig. 1. H<sub>2</sub>O<sub>2</sub> generation for WT and N61S hFMO3.** The amount of hydrogen peroxide was measured for WT (black) and N61S mutant (red) hFMO3 as a function of time after the reaction is started. A) Generation of hydrogen peroxide in the first 5 minutes. B) Generation of hydrogen peroxide for 60 minutes. Reaction conditions for the production of hydrogen peroxide: 1.6 μM hFMO3 with 160 μM NADPH at 37°C in the dark in 50 mM KPi at pH 7.4. For detection of hydrogen peroxide refer to Materials and Methods.

If we look at the overall rate of H<sub>2</sub>O<sub>2</sub> production by hFMO3 (Fig 2) the data are in agreement with recently published data [16] for this enzyme (0.5–2.5 nmol/min/nmol FMO at pH 7.4).



**Fig. 2. Rate of H<sub>2</sub>O<sub>2</sub> formation.** Calculation of the rate is performed using the linear range of the kinetics curve between 60 and 180 seconds. Reaction conditions for the production of hydrogen peroxide: 1.6  $\mu$ M hFMO3 and 160  $\mu$ M NADPH at 37°C in the dark in 50 mM KPi, pH 7.4.

Moreover, in order to better understand what is the real level of uncoupling in hFMO3, we also measured the amount of product (benzylamine N-oxide) formed as a function of NADPH consumed. As expected the WT enzyme shows overall lower uncoupling (50-70%) when compared to N61S (90-95%), as shown in Figure 3.




207 **Fig. 3. Enzyme coupling efficiency.** A) Oxidation of NADPH B) Product formation measured  
 208 as benzydamine N-oxide C) Ratio between the amount of benzydamine N-oxide formed and  
 209 the amount of NADPH consumed for WT (black) and N61S mutant (red) hFMO3. Reaction  
 210 conditions for the production of hydrogen peroxide: 1.6  $\mu$ M hFMO3, 160  $\mu$ M NADPH with 300  
 211  $\mu$ M benzydamine at 37°C in the dark in 50 mM KPi at pH 7.4.


212

213

214 Further characterization of the uncoupling process was carried out by measuring  $H_2O_2$   
 215 production under different conditions to assess the specific contribution of the substrate  
 216 benzydamine (BZD), in the presence of catalase (CAT) and superoxide dismutase (SOD). For  
 217 both WT and N61S enzymes the presence of substrate significantly lowers the formation of  
 218  $H_2O_2$  (Figure 4A, B, Figure S6). As expected, catalase totally removed the  $H_2O_2$  from the  
 219 reaction mixtures, so no  $H_2O_2$  was detected (data not shown). On the other hand, superoxide  
 220 dismutase in the absence of substrate, increased the amount of  $H_2O_2$  detected after 15 and 30  
 221 minutes suggesting the possible formation of superoxide radical (i.e. since superoxide  
 222 dismutase catalyzes the disproportionation of superoxide into  $O_2$  and  $H_2O_2$ , an increase in  $H_2O_2$   
 223 is indicative of the presence of the superoxide radical) (Figure 4A).



224






**Fig. 4. Effect of substrate, catalase (CAT) and superoxide dismutase (SOD) on  $H_2O_2$  generation.** Data obtained WT (top) and N61S (bottom) hFMO3 after 5 (black), 15 (red) or 30 (blue) minutes. Bars represent the mean  $\pm$  standard deviation. Statistically different (\*) from same time of different group,  $p < 0.05$ . Reaction conditions: 1.6  $\mu M$  hFMO3, 160  $\mu M$  NADPH, 2  $\mu M$  SOD with 2  $\mu M$  catalase at 37°C in the dark in 50 mM KPi at pH 7.4.

Subsequently, the amount of benzydamine N-oxide product formed in the absence or presence of catalase/superoxide dismutase was also calculated. For WT both catalase and superoxide dismutase have a slightly negative impact after 15 minutes on the amount of product formed (Figure 5A). In the case of N61S variant, catalase has a positive impact on catalysis after 15 minutes whereas superoxide dismutase does not seem to affect product formation.



**Fig. 5. Effect of substrate, catalase (CAT) and superoxide dismutase (SOD) on benzydamine N-oxide product formation.** Data obtained WT (top) and N61S (bottom) hFMO3 after 5 (black), 15 (red) or 30 (blue) minutes. Bars represent the mean  $\pm$  standard deviation. Statistically different (\*) from same time of different groups,  $p < 0.05$ . Reaction conditions: 1.6  $\mu\text{M}$  hFMO3, 160  $\mu\text{M}$  NADPH, 300  $\mu\text{M}$  benzydamine, 2  $\mu\text{M}$  SOD and 2  $\mu\text{M}$  catalase at 37°C in the dark in 50 mM KPi at pH 7.4.

eliminate any source of superoxide (data not shown). As shown in Figure 6, cytochrome c reduction clearly shows how both WT and N61S hFMO3 are able to form the superoxide radical and that N61S forms twice as much superoxide reaching 4  $\mu$ M after 5 minutes.



**Fig. 6. Generation of superoxide.** WT (black) and N61S mutant (red) hFMO3. A) Cytochrome c reduction in the absence of benzydamine. B) Cytochrome c reduction in the presence of benzydamine. Reaction conditions: 1.6  $\mu$ M hFMO3, 160  $\mu$ M NADPH, 300  $\mu$ M benzydamine, 10  $\mu$ M cytochrome c with 2  $\mu$ M SOD at 37°C in the dark in 50 mM KPi at pH 7.4.

Finally, taken all the data together the total amount of uncoupling measured for both hFMO3 and its N61S polymorphic variant was converted into percentages (see Materials and methods section). In the case of the WT enzyme, after 10 min of incubation with the substrate, ~62% uncoupling was calculated of which 48% is due to hydrogen peroxide with remaining 14% due to superoxide radical formation. On the other hand, under the same experimental conditions, the N61S polymorphic variant is ~98% uncoupled with 80% from hydrogen peroxide and 18% from superoxide formation.

276

#### 277 **4. Discussion**

278 Mechanistic studies carried out on pig liver FMO during the 1980's pointed unequivocally  
279 towards a precise scheme: mammalian FMO is reduced by NADPH and upon binding of oxygen  
280 can form a stable C4a-hydroperoxide intermediate [11,12]. It has been postulated that FMO is  
281 present in the cell in this highly reactive form ready to exert catalysis on its substrates [27, 28].  
282 Such mechanism was also investigated against a large number of substrates and even though  
283 the enzyme shows differential affinity for N- or S- soft nucleophiles, it is thought to lack a proper  
284 binding step during catalysis. According to this scheme, any suitable molecule can be  
285 monooxygenated by FMO, provided that charge and size characteristics are respected [27].  
286 In this context, the uncoupling reactions of FMO and its ability to generate reactive oxygen  
287 species has been considered negligible for a long time. Nevertheless, more recent studies have  
288 highlighted the fact that hFMO3 does not form a highly stable C4a-hydroperoxy intermediate  
289 [13]. UV-vis stopped-flow experiments demonstrated that WT hFMO3 forms an intermediate  
290 that can last for minutes and not for hours [13, 14]. Further characterization of the enzyme led  
291 to the confirmation that NADP<sup>+</sup> binding is crucial for the intermediate stability and that an active  
292 site mutant, N61S, dramatically decreases the affinity of the enzyme for the cofactor preventing  
293 the formation of the reaction intermediate [13, 14]. Measured K<sub>d</sub> values for NADPH are 0.3 and  
294 51.8 μM for WT and N61S hFMO3, respectively [13]. In the case of NADP<sup>+</sup> the binding affinity  
295 for WT is 3.7 μM, whereas for N61S no appreciable binding could be detected [13].  
296 Other published studies on hFMO5 have also pointed towards the absence of a stable  
297 intermediate in the reaction mechanism of the enzyme and suggested the unproductive leakage  
298 of the peroxyflavin [15]. In a recent published work by Williams and colleagues [16] the  
299 uncoupling process of human FMO isoforms 1, 2 and 3 was studied. The latter authors



300 demonstrated how all studied isoforms generate  $H_2O_2$  upon reduction by NADPH, both in the  
301 presence or absence of substrate and, unexpectedly that the presence of substrate even  
302 increased the amount of  $H_2O_2$  generated by FMO [16]. The same group did not observe any  
303 effect with the addition of catalase or superoxide dismutase to the reaction [16].

304 In this work, we undertook an extensive characterization of hFMO3 on the basis of the above-  
305 mentioned recent findings. For this reason, two purified enzymes were used: wild type hFMO3  
306 and N61S [13]. It was found that both WT and N61S produce  $H_2O_2$  (Figure 1) with higher  
307 amounts observed with the mutant due to its inability to bind  $NADP^+$  and form a stable C4a-  
308 hydroperoxy intermediate. The latter finding suggests that this mutation leads to an overall  
309 faster catalytic cycle that is detrimental for catalysis [13]. This is fully in line with previous  
310 characterization of the rates of formation and decay of the flavin intermediates reported for WT  
311 and N61S hFMO3 [13].


312 Subsequently, we focused our attention to the actual meaning of coupling i.e. the use of  
313 electrons donated by NADPH to yield a product molecule. To this end, benzydamine a hFMO3  
314 marker substrate was used and the amount of product was measured as a percentage of the  
315 NADPH consumed. The data confirmed a high degree of uncoupling for hFMO3 and an even  
316 higher increased propensity to the unproductive leakage of electrons for the N61S variant  
317 (Figure 3). More importantly, if the amount of  $H_2O_2$  produced in the absence/presence of the  
318 substrate is compared, it becomes evident that the presence of the substrate results in a strong  
319 decrease in the amount of  $H_2O_2$  (Figure 4A, B). The latter observation is actually in line with the  
320 current representation of the catalytic cycle [16].

321 All these findings indicate that there are competing paths that ultimately lead to the regeneration  
322 of the FAD cofactor: the productive path leads to product oxidation with the unproductive path  
323 leading to the formation of reactive oxygen species. Further analysis shows that both catalase

324 and superoxide dismutase slightly decrease the amount of benzydamine N-oxide formed in the  
325 enzymatic reaction for WT and have contrasting effects for N61S (Figure 5A, B). A possible  
326 explanation for the increase in product formation for WT is that N-oxidation can be achieved -  
327 at least to a much lower extent - in the absence of enzyme and only by  $H_2O_2$ , as most N-oxides  
328 are actually synthesized [29]. Nevertheless, our experiments show that incubation of  $H_2O_2$  with  
329 benzydamine does not lead to non-enzymatic product formation (Figure S7). In the case of  
330 N61S, a significant increase in the amount of product is detected after 30 minutes in presence  
331 of catalase. This could be due to the decreased protein structural damage caused by large  
332 amounts of  $H_2O_2$  in the absence of catalase after several minutes/catalytic cycles. Our data  
333 indicate that incubation of  $H_2O_2$  with hFMO3 does not lead to structural damage (Figure S8).  
334 Therefore the increased amount of product formed for N61S can only be compatible with a  
335 higher coupling efficiency in the presence of catalase.

336 In general, looking at the catalytic cycle of hFMO3 (Fig. 7) a productive oxidative half-cycle  
337 leading to N-oxidation of the substrate and an unproductive oxidative half-cycle leading to  $H_2O_2$   
338 can clearly be identified. As expected in the presence of the substrate the enzyme uses the  
339 productive path more often as confirmed by data obtained in presence of benzydamine showing  
340 that the presence of this substrate favors the coupled reaction and decreases the amount of  
341  $H_2O_2$  formed. Moreover, since a higher amount of  $H_2O_2$  was observed in the presence of  
342 superoxide dismutase, the possibility of hFMO3 producing the superoxide radical was also  
343 investigated. Cytochrome c reduction experiments confirmed hFMO3 as the source of  
344 superoxide radical. As mentioned earlier, superoxide radical formation had already been  
345 reported for pig FMO but it had been studied in close association to the possible exploitation of  
346 this reactive oxygen species for the hydroxylation of amines [17] and not in the context of the  
347 uncoupling reactions.

348 In light of the observed superoxide radical, we propose a second shunt in the catalytic cycle of  
349 hFMO3 consisting of an earlier exit from the productive path (fig. 7, steps a, b). The latter is in  
350 addition to the already reported shunt leading to  $\text{H}_2\text{O}_2$  (fig. 7, step c) as mentioned above [16].  
351 It is known that for the reduced flavin to react with oxygen a “radical pair” between the  
352 superoxide and the flavin semiquinone is formed (fig. 7 step 2) [30]. This species is highly  
353 unstable and it has never been captured [31], but it is chemically required to bypass the spin  
354 inversion barrier [30, 31]. At this point of the cycle the radical pair can either yield the  
355 hydroperoxyflavin (fig. 7 step 3-4) or take an unproductive path and generate a semiquinone  
356 radical with the loss of the superoxide (fig. 7 step a). This semiquinone intermediate can decay  
357 resulting in the re-oxidized flavin with the concomitant production of another superoxide (fig. 7  
358 step b). This new path can explain why after the formation of the caged radical pair, superoxide  
359 can detach from the flavin together with  $\text{NADP}^+$ , short circuiting the catalytic cycle.



**Fig. 7. Chemical structures of FAD reaction intermediates during the catalytic cycle of flavin-containing monooxygenases.** NADPH reduction (step 1) is rapidly followed by activation of molecular oxygen (step 2), binding on the C4a and protonation to yield the C4a-hydroperoxide (step 3-4). This intermediate can react with the substrate (S) and yield the oxygenated product (S-O, step 5). The second atom of oxygen is released as H<sub>2</sub>O (step 6) and NADP<sup>+</sup> can leave the active site (step 7). Two side reactions can occur that produce reactive oxygen species: steps a) and b) before formation of the hydroperoxyflavin after spin inversion of the radical pair which can result in the loss of superoxide or step c) the direct loss of H<sub>2</sub>O<sub>2</sub> from the C4a-hydroperoxy intermediate.

371 The physiological role of the uncoupled reaction products of hFMO3 is still unknown. It has  
372 been suggested that the generation of hydrogen peroxide by FMO could play a role in control  
373 of the overall redox state of the cell [27] or in the synthesis of protein disulfide bonds through  
374 cysteamine oxidation [32, 33]. On the other hand, toxicological effects such as hepatic injury  
375 through radical production and lipid peroxidation have also been reported in rat FMO catalyzing  
376 the oxidation of thioacetamide [34]. Initially it was thought that the products of thioacetamide,  
377 being radicals themselves, were initiating the inflammation and the resulting hepatic injury, but  
378 further investigation suggested the FMO enzyme itself might be involved [35]. Nevertheless,  
379 since this current work and others [16-18] have shown FMO enzymes to be highly uncoupled,  
380 further studies are required to confirm whatever the role of these reactive oxygen species  
381 maybe, physiological or toxicological.

382

383

#### 384 **Conflict of interest**

385 The authors declare no conflict of interest

386

#### 387 **Acknowledgement**

388 Chongliang Gao is the recipient of a PhD scholarship from University of Torino for international  
389 students. This research did not receive any specific grant from funding agencies in the public,  
390 commercial, or not-for-profit sectors.

391

392

393

394 **References**

- 395 [1] J.R. Cashman and J. Zhang, Human Flavin-Containing Monooxygenases. *Ann. Rev.*  
396 *Pharmacol. Toxicol.* 46 (2006) 65–100.
- 397 [2] I.R. Philips and E.A. Shephard, Drug metabolism by flavin-containing monooxygenases of  
398 human and mouse. *Exp. Opin. Drug Metab. Toxicol.* 13 (2017) 167–181.
- 399 [3] L. L. Poulsen and D. M. Ziegler, The liver Microsomal FAD-containing Monooxygenase J.  
400 *Biol. Chem.* 254, (1979) 6449-6455.
- 401 [4] D.H. Lang, C.K. Yeung, R.M. Peter, C. Ibarra, R. Gasser, K. Itagaki, R.M. Philpot, A.E.  
402 Rettie, Isoform specificity of trimethylamine N-oxygenation by human flavin-containing  
403 monooxygenase (FMO) and P450 enzymes - Selective catalysis by FMO3, *Biochemical*  
404 *Pharmacology* 56(8) (1998) 1005-1012.
- 405 [5] J.R. Cashman, Y.A. Bi, J. Lin, R. Youil, M. Knight, S. Forrest, E. Treacy, Human flavin-  
406 containing monooxygenase form 3: cDNA expression of the enzymes containing amino  
407 acid substitutions observed in individuals with trimethylaminuria, *Chemical Research in*  
408 *Toxicology* 10(8) (1997) 837-841.
- 409 [6] C.T. Dolphin, A. Janmohamed, R.L. Smith, E.A. Shephard, I.R. Phillips, Missense mutation  
410 in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome,  
411 *Nature Genetics* 17(4) (1997) 491-494.
- 412 [7] C.T. Dolphin, A. Janmohamed, R.L. Smith, E.A. Shephard and I. R. Phillips, Compound  
413 heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3)  
414 gene in patients with fish-odour syndrome. *Pharmacogen.* 10 (2000) 799–807.
- 415 [8] Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, A.E. Feldstein, E.B.  
416 Britt, X. Fu, Y.-M. Chung, Y. Wu, P. Schauer, J.D. Smith, H. Allayee, W.H.W. Tang, J.A. Di  
417 Donato, A.J. Lusis, S.L. Hazen, Gut flora metabolism of phosphatidylcholine promotes

cardiovascular disease, *Nature* 472 (2011) 57-82.

[9] C. Johnson, A.J. Prokopienko, R.E. West, T.D. Nolin, J.R. Stubbs, Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice, *Drug Metabolism Disposition* 46(9) (2018) 1304-1309.

[10] J.A.P. Tomlinson, D.C. Wheeler, The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease, *Kidney International* 92(4) (2017) 809-815.

[11] N.B. Beaty and D.P. Ballou, The Reductive Half-reaction of Liver Microsomal FAD-containing Monooxygenase, *Journal of Biological Chemistry*, 256(9) (1981) 4611-4618.

[12] N.B. Beaty and D.P. Ballou, The Oxidative Half-reaction of Liver Microsomal FAD-containing Monooxygenase, 256(9) (1981) 4619-4625.

[13] C.L. Gao, G. Catucci, S. Castrignano, G. Gilardi, S.J. Sadeghi, Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine, *Scientific Reports* 7 (2017).

[14] C. Gao, G. Catucci, G. Gilardi, S.J. Sadeghi, Binding of methimazole and NADP(H) to human FMO3: In vitro and in silico studies, *Int. J. Biol. Macromol.* 118 (Part A) (2018) 460-468.

[15] F. Fiorentini, M. Geier, C. Binda, M. Winkler, K. Faber, M. Hall, A. Mattevi, Biocatalytic Characterization of Human FMO5: Unearthing Baeyer-Villiger Reactions in Humans, *ACS Chemical Biology* 11(4) (2016) 1039-1048.

[16] L.K. Siddens, S.K. Krueger, M.C. Henderson, D.E. Williams, Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide, *Biochemical Pharmacology* 89(1) (2014) 141-147.

[17] E.J. Rauckman, G.M. Rosen, B.B. Kitchell, Superoxide Radical as an Intermediate in the

442        Oxidation of Hydroxylamines by Mixed Function Amine Oxidase, *Molecular Pharmacology*  
443        15(1) (1979) 131-137.

444    [18] R.E. Tynes, P.J. Sabourin, E. Hodgson, R.M. Philpot, Formation of hydrogen peroxide and  
445        N-hydroxylated amines catalyzed by pulmonary flavin-containing monooxygenases in the  
446        presence of primary alkylamines, *Archives of Biochemistry and Biophysics* 251(2) (1986)  
447        654-664.

448    [19] G. Catucci, G. Gilardi, L. Jeuken, S.J. Sadeghi, In vitro drug metabolism by C-terminally  
449        truncated human flavin-containing monooxygenase 3, *Biochemical pharmacology* 83(4)  
450        (2012) 551-8.

451    [20] S.J. Sadeghi, R. Meirinhos, G. Catucci, V.R. Dodhia, G. Di Nardo, G. Gilardi, Direct  
452        Electrochemistry of Drug Metabolizing Human Flavin-Containing Monooxygenase:  
453        Electrochemical Turnover of Benzydamine and Tamoxifen. *J. Am. Chem. Soc.* 132 (2010)  
454        458-59.

455    [21] G. Catucci, S.J. Sadeghi, G. Gilardi, A direct time-based ITC approach for substrate  
456        turnover measurements demonstrated on human FMO3,  
457        *Chemical Communications*, 55 (2019) 6217-6220.

458    [22] G. Catucci, I. Polignano, D. Cusumano, C. Medana, G. Gilardi, S.J. Sadeghi, Identification  
459        of human flavin-containing monooxygenase 3 substrates by a colorimetric screening assay,  
460        *Analytical Biochemistry* 522 (2017) 46-52.

461    [23] V. Mishin, J.P. Gray, D.E. Heck, D.L. Laskin, J.D. Laskin, Application of the Amplex  
462        red/horseradish peroxidase assay to measure hydrogen peroxide generation by  
463        recombinant microsomal enzymes, *Free Radical Biology and Medicine* 48(11) (2010) 1485-  
464        1491.

465    [24] G. Catucci, I. Zgrablic, F. Lanciani, F. Valetti, D. Minerdi, D.P. Ballou, G. Gilardi, S.J.



466 Sadeghi, Characterization of a new Baeyer-Villiger monooxygenase and conversion to a  
 467 solely N-or S-oxidizing enzyme by a single R292 mutation, *Biochimica Biophysica Acta-  
 468 Proteins and Proteomics* 1864(9) (2016) 1177-1187.

469 [25] G. Catucci, S. Bortolussi, G. Rampolla, D. Cusumano, G. Gilardi, S.J. Sadeghi Flavin-  
 470 Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of  
 471 Tamoxifen and Clomiphene, *Basic and clinical pharmacology and toxicology*, 123 (2018)  
 472 687-691.

473 [26] S. Castrignano, S. Bortolussi, G. Catucci, O. Gholami, F. Valetti, G. Gilardi, S.J. Sadeghi,  
 474 Bioelectrochemical profiling of two common polymorphic variants of human FMO3 in  
 475 presence of graphene oxide, *Electrochimica Acta* 228 (2017) 611-618.

476 [27] S.K. Krueger, D.E. Williams, Mammalian flavin-containing monooxygenases:  
 477 structure/function, genetic polymorphisms and role in drug metabolism, *Pharmacology &  
 478 Therapeutics* 106(3) (2005) 357-387.

479 [28] G. Catucci, C.L. Gao, S.J. Sadeghi, G. Gilardi, Chemical applications of Class B  
 480 flavoprotein monooxygenases, *Rendiconti Lincei-Scienze Fisiche E Naturali* 28 (2017) 195-  
 481 206.

482 [29] K. Bergstad, J.E. Backvall, Mild and efficient flavin-catalyzed H<sub>2</sub>O<sub>2</sub> oxidation of tertiary  
 483 amines to amine N-oxides, *Journal of Organic Chemistry* 63(19) (1998) 6650-6655.

484 [30] V. Massey, Activation of molecular-oxygen by flavins and flavoproteins, *Journal of  
 485 Biological Chemistry* 269(36) (1994) 22459-22462.

486 [31] P. Chaiyen, M.W. Fraaije, A. Mattevi, The enigmatic reaction of flavins with oxygen, *Trends  
 487 in Biochemical Sciences* 37(9) (2012) 373-380.

488 [32] L.L. Poulsen, D.M. Ziegler, Microsomal mixed-function oxidase-dependent renaturation of  
 489 reduced ribonuclease. *Arch Biochem Biophys* 183 (1977) 565–570.

490 [33] D. M. Ziegler, M. W. Duffel, L. L. Poulsen, Studies on the nature and regulation of the  
491 cellular thio:disulphide potential. Ciba Found Symp 72 (1979), 191– 204.

492 [34] P.V. Reddy, Ch.R. Murthy, P. Reddanna, Fulminant hepatic failure induced oxidative stress  
493 in nonsynaptic mitochondria of cerebral cortex in rats. Neurosci. Lett. 368, (2004) 15–20.

494 [35] D.Z. Hsu, P.Y Chu., Y.H. Li, V.R. Chandrasekaran., M.Y. Liu, Role of flavin-containing-  
495 monooxygenase-dependent neutrophil activation in thioacetamide-induced hepatic  
496 inflammation in rats. Toxicology 298, (2012) 52-58.

497

498